Rudy Li
Stock Analyst at Wolfe Research
(4.95)
# 21
Out of 5,179 analysts
39
Total ratings
73.17%
Success rate
80.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | $40 | $28.70 | +39.37% | 5 | Feb 24, 2026 | |
| ALKS Alkermes | Initiates: Outperform | $45 | $29.39 | +53.11% | 1 | Feb 24, 2026 | |
| AXSM Axsome Therapeutics | Initiates: Outperform | $230 | $156.35 | +47.11% | 1 | Feb 24, 2026 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $60 | $54.48 | +10.13% | 5 | Feb 24, 2026 | |
| STOK Stoke Therapeutics | Initiates: Outperform | $40 | $32.85 | +21.77% | 5 | Feb 24, 2026 | |
| QURE uniQure | Initiates: Peer Perform | n/a | $14.77 | - | 1 | Feb 24, 2026 | |
| DNLI Denali Therapeutics | Initiates: Peer Perform | n/a | $18.16 | - | 1 | Feb 24, 2026 | |
| PRAX Praxis Precision Medicines | Initiates: Outperform | $500 | $290.10 | +72.35% | 4 | Feb 24, 2026 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $160 | $128.32 | +24.69% | 1 | Feb 24, 2026 | |
| DFTX Definium Therapeutics | Initiates: Outperform | $25 | $17.88 | +39.82% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $20.75 | +59.04% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $70.10 | +14.12% | 3 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $1.09 | +175.23% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $20.50 | -26.83% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.74 | +5,293.74% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 | $9.26 | +94.38% | 7 | Aug 28, 2025 |
Centessa Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $28.70
Upside: +39.37%
Alkermes
Feb 24, 2026
Initiates: Outperform
Price Target: $45
Current: $29.39
Upside: +53.11%
Axsome Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $230
Current: $156.35
Upside: +47.11%
Xenon Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $60
Current: $54.48
Upside: +10.13%
Stoke Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $32.85
Upside: +21.77%
uniQure
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $14.77
Upside: -
Denali Therapeutics
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $18.16
Upside: -
Praxis Precision Medicines
Feb 24, 2026
Initiates: Outperform
Price Target: $500
Current: $290.10
Upside: +72.35%
Neurocrine Biosciences
Feb 24, 2026
Initiates: Outperform
Price Target: $160
Current: $128.32
Upside: +24.69%
Definium Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $25
Current: $17.88
Upside: +39.82%
Feb 24, 2026
Initiates: Outperform
Price Target: $33
Current: $20.75
Upside: +59.04%
Jan 2, 2026
Maintains: Buy
Price Target: $80
Current: $70.10
Upside: +14.12%
Sep 29, 2025
Initiates: Buy
Price Target: $3
Current: $1.09
Upside: +175.23%
Sep 29, 2025
Initiates: Buy
Price Target: $15
Current: $20.50
Upside: -26.83%
Sep 29, 2025
Initiates: Buy
Price Target: $40
Current: $0.74
Upside: +5,293.74%
Aug 28, 2025
Maintains: Buy
Price Target: $18
Current: $9.26
Upside: +94.38%